利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.035 秒)

    Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
    6.
    发明申请
    Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections 审中-公开
    使用EphA2和EphrinA1调节剂治疗和预防感染

    公开(公告)号：US20060121043A1

    公开(公告)日：2006-06-08

    申请号：US11259266

    申请日：2005-10-27

    申请人： Michael Kinch ,  Kelly Carles-Kinch

    发明人： Michael Kinch ,  Kelly Carles-Kinch

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  Y02A50/403 ,  Y02A50/41

    摘要： The present invention provides methods and compositions designed for the treatment, management, and/or amelioration of an infection, in particular an intracellular pathogen infection, such as a viral, bacterial, protozoa or fungal infection. In particular, the present invention provides methods for treating, managing, preventing and/or ameliorating an infection where the expression of EphA2 is upregulated in infected cells (e.g., infected epithelial cells), said methods comprising administering to a subject an effective amount of one or more EphA2/EphrinA1 Modulators. In accordance with the present invention, such methods may also comprise the administration of one or more therapies other than an EphA2/EphrinA1 Modulator. The present invention also provides pharmaceutical compositions comprising EphA2/EphrinA1 Modulators, and optionally, one or more prophylactic or therapeutic agents other than an EphA2/EphrinA1 Modulator, and the use of such compositions in the treating, management, prevention and/or amelioration of an infection. Further provided by the invention are articles of manufacture and kits comprising an EphA2/EphrinA1 Modulator of the invention, and, optionally, other prophylactic or therapeutic agents (e.g., immunomodulatory agents, anti-viral agents, anti-inflammatory agents, anti-bacterial agents, anti-fungal agents, etc.).

    摘要翻译： 本发明提供了用于治疗，管理和/或改善感染，特别是细胞内病原体感染如病毒，细菌，原生动物或真菌感染的方法和组合物。 特别地，本发明提供了用于治疗，控制，预防和/或改善感染的方法，其中EphA2的表达在受感染的细胞（例如感染的上皮细胞）中被上调，所述方法包括向受试者施用有效量的一种 或更多的EphA2 / EphrinA1调节剂。 根据本发明，这些方法还可以包括施用除EphA2 / EphrinA1调节剂之外的一种或多种治疗。 本发明还提供包含EphA2 / EphrinA1调节剂的药物组合物，以及任选的除EphA2 / EphrinA1调节剂之外的一种或多种预防或治疗剂，以及这些组合物在治疗，管理，预防和/或改善 感染。 本发明进一步提供的是包含本发明的EphA2 / EphrinA1调节剂和任选的其它预防或治疗剂（例如免疫调节剂，抗病毒剂，抗炎剂，抗菌剂 ，抗真菌剂等）。

    ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER
    8.
    发明申请
    ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER 审中-公开
    用于诊断和治疗前列腺癌的抗体

    公开(公告)号：US20110206695A1

    公开(公告)日：2011-08-25

    申请号：US13013002

    申请日：2011-01-25

    申请人： Manu Kohli ,  Michael Goldblatt ,  Michael Kinch

    发明人： Manu Kohli ,  Michael Goldblatt ,  Michael Kinch

    IPC分类号： A61K39/395 ,  C12Q1/70 ,  A61P35/00

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K16/28 ,  G01N33/57434 ,  G01N2333/15

    摘要： XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival.

    摘要翻译： XMRV似乎与前列腺癌相关，如果它感染男性生殖细胞和慢性疲劳综合征两性。 （如果病毒不感染生殖细胞）。 前列腺癌细胞只有在感染了像XMRV这样的病毒时才在表面上显示TSG101。 对TSG101的抗体可以有效地诊断以鉴别具有前列腺炎倾向的个体。 它们也可以用于代替目前的诊断以确认前列腺癌的存在。 TSG101抗体在体内施用时，具有减少肿瘤大小，抑制转移转化和延长存活的能力。